Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus. After all, the birds are still chirping and a cool breeze is wafting by. Moreover, this marks the middle of the week, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Remember, no prescription is required. Meanwhile, here are a few items of interest. Have a grand day and drop us a line if you hear something saucy. …

With its $74 billion acquisition of Celgene (CELG) set to be final later this year, Bristol-Myers Squibb (BMY) disclosed its new executive lineup, STAT notes. One notable absence from the roster: Chief Scientific Officer Dr. Tom Lynch, the pioneering oncologist who joined the company in March 2017. And one of the biggest changes will be that operations overseen by Lynch will be split into two different roles: One executive will run research and early development, while another will run late-stage development.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • File the last sentence under ‘The FDA really can’t win lately.’ And so JAMA pummels the FDA for not doing something when “Currently, regulations prohibit the FDA from disclosing the applications.”
    Sad that a federal agency would follow the regulations, isn’t it? (Pardon my irony …)

Comments are closed.